Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ciclesonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 11/20 | 1.00 |
| ▸ | PGR | P06401 | 7/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.59 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.59 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | IL5 | P05113 | 1/20 | 0.59 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.59 |
| ▸ | AR | P10275 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | MMP9 | P14780 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | THPO | P40225 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ciclesonide SCHEMBL15830978 | 1.00 | NR3C1 (1.00) | NR3C1PGRNR1I2ADORA3CNR1 | |
| Ciclesonide SCHEMBL1753411 | 1.00 | NR3C1 (1.00) | NR3C1PGRNR1I2ADORA3CNR1 | |
| Ciclesonide SCHEMBL3688 | 1.00 | NR3C1 (1.00) | NR3C1PGRNR1I2ADORA3CNR1 | |
| Ciclesonide SCHEMBL4782166 | 1.00 | NR3C1 (1.00) | NR3C1PGRNR1I2ADORA3CNR1 | |
| Ciclesonide SCHEMBL14493775 | 1.00 | NR3C1 (1.00) | NR3C1PGRNR1I2ADORA3CNR1 | |
| Ciclesonide SCHEMBL1244607 | 1.00 | NR3C1 (1.00) | NR3C1PGRNR1I2ADORA3CNR1 | |
| Ciclesonide SCHEMBL13575757 | 1.00 | NR3C1 (1.00) | NR3C1PGRNR1I2ADORA3CNR1 | |
| Ciclesonide SCHEMBL17439183 | 1.00 | NR3C1 (1.00) | NR3C1PGRNR1I2ADORA3CNR1 | |
| Ciclesonide SCHEMBL13014882 | 1.00 | NR3C1 (1.00) | NR3C1PGRNR1I2ADORA3CNR1 | |
| Ciclesonide SCHEMBL5700709 | 1.00 | NR3C1 (1.00) | NR3C1PGRNR1I2ADORA3CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024482-A1 | PHARMACEUTICAL FORMULATION COMPRISING CICLESONIDE | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2024-01-25 | — | — | US | disclosed |
| US-20240024482-A1 | PHARMACEUTICAL FORMULATION COMPRISING CICLESONIDE | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2024-01-25 | — | — | US | disclosed |
| US-11819549-B2 | Pharmaceutical formulation comprising ciclesonide | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-11-21 | — | — | US | disclosed |
| US-11819549-B2 | Pharmaceutical formulation comprising ciclesonide | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-11-21 | — | — | US | disclosed |
| EP-3473255-B1 | PHARMACEUTICAL FORMULATION COMPRISING CICLESONIDE | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2022-01-12 | — | — | EP | disclosed |
| US-20210106685-A1 | PHARMACEUTICAL FORMULATION COMPRISING CICLESONIDE | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2021-04-15 | — | — | US | disclosed |
| EP-3473255-A1 | PHARMACEUTICAL FORMULATION COMPRISING CICLESONIDE | Boehringer Ingelheim Vetmedica GmbH (DE) | 2019-04-24 | — | — | EP | disclosed |
| US-20140179650-A1 | PHARMACEUTICAL FORMULATION COMPRISING CICLESONIDE | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2014-06-26 | — | — | US | disclosed |
| US-20140179650-A1 | PHARMACEUTICAL FORMULATION COMPRISING CICLESONIDE | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2014-06-26 | — | — | US | disclosed |
| US-20120058980-A1 | AEROSOL FORMULATION FOR THE INHALATION OF BETA AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-08 | — | — | US | disclosed |
| US-20120058980-A1 | AEROSOL FORMULATION FOR THE INHALATION OF BETA AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-08 | — | — | US | disclosed |
| US-20080041370-A1 | AEROSOL FORMULATION FOR THE INHALATION OF BETA AGONISTS | RADAU KIRSTEN | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058980-A1 | AEROSOL FORMULATION FOR THE INHALATION OF BETA AGONISTS | ADRB2, ADRB1, ADRB3 | NR3C1 776/4885PGR 1436/4885NR1I2 514/4885 |
| US-20140179650-A1 | PHARMACEUTICAL FORMULATION COMPRISING CICLESONIDE | CYP11B2, CYP11B1, MC2R | NR3C1 8/4885PGR 333/4885NR1I2 433/4885 |
| US-20210106685-A1 | PHARMACEUTICAL FORMULATION COMPRISING CICLESONIDE | CYP11B2, MC2R, CYP11B1 | NR3C1 5/4885PGR 236/4885NR1I2 492/4885 |
| US-20240024482-A1 | PHARMACEUTICAL FORMULATION COMPRISING CICLESONIDE | CYP11B2, MC2R, CYP11B1 | NR3C1 5/4885PGR 236/4885NR1I2 492/4885 |
| US-11819549-B2 | Pharmaceutical formulation comprising ciclesonide | CYP11B2, MC2R, CYP11B1 | NR3C1 5/4885PGR 236/4885NR1I2 492/4885 |
| US-20080041370-A1 | AEROSOL FORMULATION FOR THE INHALATION OF BETA AGONISTS | ADRB2, ADRB1, ADRA2A | NR3C1 855/4885PGR 1415/4885NR1I2 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.